TY - JOUR
T1 - Ventral hernia following primary laparotomy for ovarian, fallopian tube, and primary peritoneal cancers
AU - Long, Kara C.
AU - Levinson, Kimberly L.
AU - Diaz, John P.
AU - Gardner, Ginger J.
AU - Chi, Dennis S.
AU - Barakat, Richard R.
AU - Leitao, Mario M.
PY - 2011/1/1
Y1 - 2011/1/1
N2 - Objectives: To evaluate the incidence and risk factors for ventral hernia development following primary laparotomy for ovarian, fallopian tube, and peritoneal cancers. Methods: All patients who underwent primary laparotomy for ovarian, tubal, or peritoneal cancer from 3/05 to 12/07 were identified. Hernias were identified radiographically or during physical exam. One-year and 2-year hernia rates were calculated. Clinicopathologic factors were evaluated for an association with the development of hernia using univariate and multivariate analysis. Results: We identified 239 cases with 12 months of follow-up. Median age was 60 years (17-89 years), and median body mass index (BMI) was 25.0 kg/m2 (16.9-58.5 kg/m2). Advanced stage disease (FIGO stage III/IV) was diagnosed in 182/239 (76%). The 1-year hernia rate was 8.8% (21/239): 13/21 (61.9%) were symptomatic, and 8/21 (38.1%) underwent hernia repair operations. On multivariate analysis, only BMI (p = 0.004) and intraperitoneal (IP) chemotherapy (p = 0.016) retained their independent association with hernia development by 12 months. Of the 239 patients, 167 had 24 months of follow-up. The 2-year hernia rate was 23.4% (39/167): 25/39 (64.1%) were symptomatic, and 17/39 (43.6%) underwent hernia repair operations. Multivariate analysis in this group demonstrated that advanced stage (p = 0.033), wound complications (p = 0.029), and BMI (p = 0.012) were independently associated with hernia development by 24 months. Conclusions: The development of ventral hernia is a significant postoperative morbidity in patients undergoing primary surgery for ovarian, tubal, or peritoneal cancer. Independent associations with hernia development include: BMI and IP chemotherapy by Year 1, and BMI, wound complications and advanced stage by Year 2.
AB - Objectives: To evaluate the incidence and risk factors for ventral hernia development following primary laparotomy for ovarian, fallopian tube, and peritoneal cancers. Methods: All patients who underwent primary laparotomy for ovarian, tubal, or peritoneal cancer from 3/05 to 12/07 were identified. Hernias were identified radiographically or during physical exam. One-year and 2-year hernia rates were calculated. Clinicopathologic factors were evaluated for an association with the development of hernia using univariate and multivariate analysis. Results: We identified 239 cases with 12 months of follow-up. Median age was 60 years (17-89 years), and median body mass index (BMI) was 25.0 kg/m2 (16.9-58.5 kg/m2). Advanced stage disease (FIGO stage III/IV) was diagnosed in 182/239 (76%). The 1-year hernia rate was 8.8% (21/239): 13/21 (61.9%) were symptomatic, and 8/21 (38.1%) underwent hernia repair operations. On multivariate analysis, only BMI (p = 0.004) and intraperitoneal (IP) chemotherapy (p = 0.016) retained their independent association with hernia development by 12 months. Of the 239 patients, 167 had 24 months of follow-up. The 2-year hernia rate was 23.4% (39/167): 25/39 (64.1%) were symptomatic, and 17/39 (43.6%) underwent hernia repair operations. Multivariate analysis in this group demonstrated that advanced stage (p = 0.033), wound complications (p = 0.029), and BMI (p = 0.012) were independently associated with hernia development by 24 months. Conclusions: The development of ventral hernia is a significant postoperative morbidity in patients undergoing primary surgery for ovarian, tubal, or peritoneal cancer. Independent associations with hernia development include: BMI and IP chemotherapy by Year 1, and BMI, wound complications and advanced stage by Year 2.
KW - Fallopian tube cancer
KW - Hernia
KW - Laparotomy
KW - Ovarian cancer
KW - Primary peritoneal cancer
UR - http://www.scopus.com/inward/record.url?scp=78649907745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649907745&partnerID=8YFLogxK
U2 - 10.1016/j.ygyno.2010.09.015
DO - 10.1016/j.ygyno.2010.09.015
M3 - Article
C2 - 20947151
AN - SCOPUS:78649907745
SN - 0090-8258
VL - 120
SP - 33
EP - 37
JO - Gynecologic oncology
JF - Gynecologic oncology
IS - 1
ER -